investment broker

One hundred years ago Thursday, the first Ford Model TT truck rolled out of the assembly plant, beginning an American love affair with pickups that still burns hot.

Henry Ford had no idea what hed begun when he had the TT engineered specifically to be a truck at a time when most pickups were modified cars.

He intended the Model TT for farmers, another tool like the Fordson tractors he built for the rural life he idealized.

He wouldve tipped his straw boater hat back, squinted and laughed in your face if you told him the F-series pickup thats the direct descendant of his Model TT would eventually become Americas best-selling vehicle, as the F-Series has been for the last35 years.

FacebookTwitterGoogle+LinkedIn100 years of Ford pickup trucks FullscreenPost to FacebookPosted!

A link has been posted to your Facebook feed.

investment broker: Knight Transportation, Inc.(KNX)

Advisors’ Opinion:

  • [By Rich Smith]

    Knight Transportation (NYSE:KNX) is merging with Swift Transportation (NYSE:SWFT) to build a $5 billion trucking behemoth — and Wall Street thinks that’s a good thing.

investment broker: ABM Industries Incorporated(ABM)

Advisors’ Opinion:

  • [By Lisa Levin]

    ABM Industries, Inc. (NYSE: ABM) was down, falling around 16 percent to $36.98 after the company posted weak Q4 earnings and issued a downbeat full-year forecast.

investment broker: Advanced Energy Industries, Inc.(AEIS)

Advisors’ Opinion:

  • [By Nelson Hem]

    While short sellers shied away from many of the leading solar stocks between the January 15 and January 29 settlement dates, two companies in particular led that trend. The number of Advanced Energy Industries, Inc. (NASDAQ: AEIS) and Sunedison Inc (NYSE: SUNE) shares sold short shrank by more than 10 percent by the end of the month.

investment broker: Zogenix, Inc.(ZGNX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Zogenix, Inc. (NASDAQ: ZGNX) was down, falling around 8 percent to $35.82 after the company disclosed new efficacy and safety data from its pivotal Phase 3 clinical trial of ZX008 in Dravet syndrome.

  • [By Lisa Levin]

    Zogenix, Inc. (NASDAQ: ZGNX) was down, falling around 11 percent to $34.75 after the company disclosed new efficacy and safety data from its pivotal Phase 3 clinical trial of ZX008 in Dravet syndrome.

Leave a Reply

Your email address will not be published. Required fields are marked *